HC Wainwright Forecasts VolitionRx's Q4 Earnings (NYSE:VNRX)

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

VolitionRx Limited (NYSE:VNRX - Free Report) - Equities researchers at HC Wainwright dropped their Q4 2025 earnings per share estimates for VolitionRx in a research note issued on Monday, August 18th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of $0.04 for the quarter, down from their previous estimate of $0.09. The consensus estimate for VolitionRx's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for VolitionRx's Q2 2026 earnings at $0.04 EPS and Q4 2026 earnings at $0.04 EPS.

VNRX has been the topic of a number of other research reports. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 target price on the stock in a research report on Tuesday, June 10th. D. Boral Capital restated a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a research report on Friday, August 15th. Finally, Wall Street Zen started coverage on VolitionRx in a research report on Thursday, May 15th. They issued a "sell" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $3.50.

VolitionRx Stock Up 1.0%

NYSE:VNRX traded up $0.0070 on Tuesday, reaching $0.6880. The company's stock had a trading volume of 151,691 shares, compared to its average volume of 196,231. VolitionRx has a 12-month low of $0.3951 and a 12-month high of $0.94. The firm has a market cap of $74.03 million, a price-to-earnings ratio of -1.91 and a beta of 1.26. The stock has a 50 day moving average price of $0.71 and a 200 day moving average price of $0.59.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VNRX. Two Sigma Securities LLC purchased a new stake in VolitionRx during the 4th quarter worth about $29,000. Blair William & Co. IL purchased a new stake in VolitionRx during the 2nd quarter worth about $30,000. Millennium Management LLC purchased a new stake in VolitionRx during the 4th quarter worth about $36,000. Northwestern Mutual Wealth Management Co. purchased a new stake in VolitionRx during the 2nd quarter worth about $52,000. Finally, Northern Trust Corp lifted its holdings in VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company's stock worth $71,000 after buying an additional 28,579 shares during the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Guy Archibald Innes acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the director owned 966,814 shares of the company's stock, valued at $618,760.96. This represents a 8.79% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Cameron John Reynolds acquired 78,125 shares of the company's stock in a transaction dated Tuesday, August 5th. The stock was purchased at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief executive officer directly owned 2,609,847 shares of the company's stock, valued at approximately $1,670,302.08. This represents a 3.09% increase in their position. The disclosure for this purchase can be found here. Insiders bought 188,750 shares of company stock valued at $118,175 over the last ninety days. Insiders own 10.40% of the company's stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.